Finally, a physician who draws the diagram.
Lupus management built on serial biomarker tracking, SLEDAI-2K scoring, and the belief that every patient deserves to understand their own immune system. If you have been dismissed, misdiagnosed, or simply told "your labs are normal" — this is the intake form for you.
How long have you been managing lupus symptoms?
This helps us understand where you are in your diagnostic journey.
The machinery, explained. Nothing proprietary. Nothing hidden.
Below is the exact four-phase process we use with every lupus patient. The tools are named. The scoring systems are cited. The timelines are real. We believe that understanding your own disease is not optional — it is the first line of defense.
Comprehensive Panel Review
Mapping your immune landscape
Before any treatment decision, we reconstruct your complete serological history. Most patients arrive with fragments — an ANA here, a CBC there. We request the full picture: anti-dsDNA antibodies, complement levels C3 and C4, anti-Smith, anti-Ro/La, phospholipid antibodies, and a complete metabolic panel. We read these not as single data points but as a timeline.
"Think of this as pulling every piece of evidence out of the drawer and laying it on the table chronologically. We are looking for patterns — not just whether a value is high, but whether it is rising, falling, or fluctuating."
What we track
- Anti-dsDNA antibody titers over time
- C3 and C4 complement consumption
- ANA titer and pattern changes
- Urinalysis protein-to-creatinine ratio
Disease Activity Scoring
Putting a number on how active your lupus is
We use the SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) — the validated clinical instrument used in lupus research trials worldwide. It scores 24 clinical and laboratory parameters to produce a number between 0 and 105. A score above 4 indicates active disease. Above 12 indicates severe activity requiring escalated intervention.
"Instead of "you seem like you're flaring," we give you a number. Then we give you that same number at every visit. You watch it go down. You understand why. When it rises, we act before you are in the emergency room."
What we track
- SLEDAI-2K score at every visit
- Individual domain scores (renal, CNS, musculoskeletal)
- PGA (Physician Global Assessment) 0–3 scale
- Cumulative organ damage via SLICC index
Treatment Protocol Selection
Matching the intervention to the evidence
Lupus treatment is not a ladder you climb rung by rung — it is a matrix determined by organ involvement, disease activity score, prior medication history, and your personal risk tolerance. We document every medication adjustment with the reasoning behind it. No black-box decisions. If we are choosing between hydroxychloroquine optimization and mycophenolate mofetil, we explain the tradeoff in writing.
"Every medication decision comes with a one-page summary: what the drug does, why we chose it for your specific profile, what we are watching for, and what the exit criteria are if it is not working."
What we track
- Hydroxychloroquine blood levels (target: 750–1200 ng/mL)
- eGFR and urinary protein for nephroprotection
- CBC and LFTs for immunosuppressant monitoring
- Ophthalmology screening schedule for HCQ
Flare Prevention Mapping
Building your personal early-warning system
Every patient has a unique flare signature — the specific combination of lab changes, symptoms, and triggers that precede their flares. We identify yours. By tracking your anti-dsDNA trend alongside your SLEDAI score over 6–12 months, we establish your personal baseline and your personal alarm threshold. When your anti-dsDNA ratio exceeds 3x baseline, we act — not wait.
"Most patients have been told "come back if you feel worse." We tell you: "If your anti-dsDNA rises above X, call us that week." You leave with a number, not a feeling."
What we track
- Personal anti-dsDNA baseline and alert threshold
- Complement nadir and recovery pattern
- Documented flare triggers (UV, infection, stress, hormonal)
- Patient-reported outcome measures (PROMIS, LupusQoL)
Download Your Lupus Lab Tracker
A printable PDF designed to teach you how to chart your own C3, C4, and anti-dsDNA values between visits. Track trends, not single data points. Understand when to call before you feel the flare.
Used by 2,400+ lupus patients. Updated with 2025 reference ranges.
Lupus Lab Tracker
Patient Reference Guide
Anti-dsDNA
Rising titer = early flare warning
Normal: < 10
IU/mL
C3 Complement
Low = active immune consumption
Normal: 0.9–1.8
g/L
C4 Complement
Low C4 + low C3 = nephritis risk
Normal: 0.1–0.4
g/L
SLEDAI-2K
>4 = active disease; >12 = severe
Normal: 0
score
Your Anti-dsDNA Trend
Bring this chart to every appointment
The binder people. The dismissed patients. Finally heard.
These are patients who arrived with years of dismissed lab work and left with a physician who reads every portal message, numbers every visit note, and answers the question no one else would answer.
7.5 years
Average diagnostic delay for lupus patients nationwide
47%
Of lupus patients are initially misdiagnosed
< 8 weeks
Average time to diagnosis with our comprehensive panel
94%
Patient satisfaction at 12-month follow-up
"I spent six years being told my joint pain was anxiety and my butterfly rash was rosacea. I arrived at my first appointment with a three-inch binder. My physician sat down, opened it, and said — "let's go through this together." She found the pattern in my ANA results that two previous rheumatologists had dismissed. My SLEDAI score was 14 on day one."
Priya Venkataraman
Diagnosed after 6-year delay · Houston, TX
"The whiteboard moment was real. She drew my complement cascade — C1, C3, C4 — and showed me exactly where the breakdown was happening and why my kidneys were being affected. I have a master's degree and no one had ever explained this to me. I left that appointment with a printed diagram, a lab tracker, and my first real treatment plan."
Marcus Okafor
SLE with renal involvement · Atlanta, GA
"My previous rheumatologist checked my ANA once a year and called it good. Here, I get anti-dsDNA and complement levels every 3 months, and I get a trend graph in my portal. When my anti-dsDNA went from 18 to 54 IU/mL between visits, we caught the flare before I was in the hospital. That is the difference."
Danielle Rousseau
Flare prevention patient · New Orleans, LA
Patient privacy: Names and identifying details are shared with explicit written consent. Clinical details (SLEDAI scores, lab values) have been confirmed accurate with each patient.
Request a Records Review
Upload your existing lab work and provide your current medication list. A clinical team member will review your records and provide a preliminary assessment before your first appointment. No obligation to schedule.
Your files are encrypted end-to-end. HIPAA-compliant storage. No third-party sharing.
A board-certified rheumatologist reviews your ANA panels, anti-dsDNA titers, and complement levels.
You receive a written summary of findings within 2 business days. Patterns identified. Questions raised.